ELGX Financial Facts
Clinical and regulatory affairs: 2.36MRevenue: 29.78M
See Full Income Statement
See Full Balance Sheet
Earnings History for Endologix Inc. (ELGX)
|
Expand Research on ELGX
| Next EPS Date | 7/25/13 *Est. | EPS Growth Rate | 0.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -79.2% | Revenue Growth Rate | +21.6% *Last Qtr. |
| Average % Move 1-Wk after EPS | -4.9% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
4/30/13  |
 |
Q113 | -$0.07 | -$0.06 | -$0.01 | $29.8M | $29.2M | N/A / N/A | = | -7.4% | Details |
| 2/27/13 |
|
Q412 | -$0.09 | -$0.03 | -$0.06 | $29.2M | $29.03M | N/A / N/A | = | -6.9% | Details |
| 10/25/12 |
Q312 | -$0.03 | -$0.04 | +$0.01 | $26.7M | $26.36M | N/A / N/A | = | +5.5% | Details | |
| 7/26/12 |
|
Q212 | -$0.09 | -$0.04 | -$0.05 | $25.5M | $25.23M | N/A / N/A | = | 0% | Details |
| 4/26/12 |
|
Q112 | -$0.07 | -$0.06 | -$0.01 | $24.5M | $23.29M | N/A / N/A | = | -2% | Details |
| 2/22/12 |
|
Q411 | -$0.06 | -$0.05 | -$0.01 | $23.4M | $23.67M | N/A / N/A | = | +10.3% | Details |
| 10/27/11 |
|
Q311 | -$0.09 | -$0.07 | -$0.02 | $22.3M | $20.14M | N/A / N/A |  |
+28.2% | Details |
| 7/21/11 |
|
Q211 | -$0.09 | -$0.07 | -$0.02 | $19.2M | $19.28M | N/A / N/A | |
+44.1% | Details |
